Read More

Intellia Therapeutics To Present Updated Interim Clinical Data From Ongoing Phase 1/2 Study Of NTLA-2002 For The Treatment Of Hereditary Angioedema At The 2022 ACAAI Annual Scientific Meeting

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that an abstract

NTLA